Effects of physical activity on placental analytes in nulliparous persons

Eur J Obstet Gynecol Reprod Biol. 2024 Jan:292:158-162. doi: 10.1016/j.ejogrb.2023.11.018. Epub 2023 Nov 15.

Abstract

Introduction: Physical activity during pregnancy has long been investigated for its role in preeclampsia prevention. The mechanism of this relationship is unknown, although some studies suggest physical activity may affect placental analytes throughout pregnancy. The objective of this study was to determine the effect of physical activity on preeclampsia-associated placental analytes using a prospective cohort of pregnant nulliparous patients.

Methods: This was a secondary analysis of the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be. Frequency and duration of up to three leisure activities was reported in the first and second trimesters and was analyzed, with participants either meeting or not meeting the recommended exercise of 150 min per week. Levels of the following placental analytes, placental growth factor, soluble endoglin, and soluble fms-like tyrosine kinase-1 (sFLT1), were analyzed stratified by the physical activity level.

Results: A total of 1,956 participants were included in the analysis. The level of sFLT1 in the first trimester was lower in the group that had ≥ 150 min per week of physical activity, compared to the group that had < 150 min (846.3 [821.6, 871,8] versus 893.0 [864.5,922.5], p = 0.017). There were no significant sFLT1 changes in the second trimester based on physical activity. After controlling for maternal demographic and clinical factors, sFLT1 levels in the second trimester were significantly lower (p = 0.049) in participants that had ≥ 150 min of physical activity per week.

Discussion: Our findings of decreased sFLT1 levels suggest this could be the mechanism explaining the association between PA in pregnancy and lower risk of preeclampsia.

Keywords: Endoglin (ENG); Nulliparous; Physical activity; Placenta; Placental growth factor (PIGF); Preeclampsia; Soluble fms-like tyrosine kinase-1 (sFlt-1); nuMoM2b.

MeSH terms

  • Biomarkers
  • Female
  • Humans
  • Placenta Growth Factor
  • Placenta*
  • Pre-Eclampsia*
  • Pregnancy
  • Pregnancy Outcome
  • Prospective Studies
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1

Substances

  • Placenta Growth Factor
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor A
  • Biomarkers